The weak Japanese economy has been cited as the chief cause behind the present situation the Japanese pharmaceutical companies are finding themselves in. However the companies are expecting that the biyearly decrease in price might be changing the scenario.
The experts feel that in order for the Japanese pharmaceutical companies to do well in the near future the national government should be taking steps to make sure that the prices of healthcare products come down.
In all probability the Japanese pharmaceutical companies are unlikely to witness a major turnaround before 2011. Presently the companies as well as the overall market are going through an extremely critical phase. The pharmaceutical companies have been gearing up to face the challenges posed by the ultra competitive international medicine market.
The rules and regulations regarding the pharmaceutical industry are being changed by the Japanese government. The pharmaceutical companies have been taking note of such situation. They are queuing up to avail the favorable conditions.
In the wake of the current industrial and economic situation it is being assumed that more Japanese pharmaceutical companies would either emerge with outstation companies or be owned by them. Presently the top pharmaceutical companies in Japan are:
- Takeda
- Pfizer
- Daiichi Sankyo
- Eisai
- Roche (Chugai)
- Taisho
- Dainippon Sumitomo
- Novartis
- Mitsubishi Pharma
- Astellas
The Japanese indigenous pharmaceutical companies are the prime forces in the Japanese market. These Japanese pharmaceutical companies however have been held back by their own inability to capture the western pharmaceutical market and the shortcomings in their own economy.
Of all the Japanese pharmaceutical companies only Takeda is counted amongst the best twenty pharmaceutical companies in the world. Despite the various problems that continue to affect them the research and development facilities of the Japanese pharmaceutical companies are significant.
